Drug Profile
B 6018
Alternative Names: B6018Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator Samyang Biopharmaceuticals Corporation
- Class Anti-infectives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Infections
Most Recent Events
- 31 Aug 2023 Discontinued - Preclinical for Infections in South Korea (Parenteral) (Samyang Biopharmaceuticals Corporation pipeline; August 2023)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Infections in South Korea (Parenteral)
- 02 Mar 2016 Preclinical trials in Infections in South Korea (Parenteral) before March 2016